Make pain visible.
Make it objective.
A personalized pain-solution R&D company, built on bioelectrical-impedance analysis.
Pain-care medical devices, redefined on data
Red & Blue is a medical-device R&D company focused on pain management.
We were the first to commercialize a technology that visualizes and objectifies pain — turning subjective patient reports into measurable bioelectrical-impedance data.
Backed by a CEO with 30 years of pain-clinic experience and a network of more than 1,800 physician members, we develop solutions that connect diagnosis, treatment, and management.
- 01WORLD'S FIRST
Pain visualization & objectification
Trigger points are identified by electrical-impedance differences. Healthy areas appear blue; trigger points appear red.
- 022 IN 1
Diagnosis and therapy in one device
PAIN BOT screens trigger points, then delivers ultrasound (SONO) and low-frequency (TENS) therapy from the same unit.
- 03EXPERTISE
30-year pain-clinic CEO
A medical doctor and former Hospital Director (Yesan Myeongji Hospital) designs the products from clinical practice.
- 04PROVEN
Validated by an SCI paper
Published in MDPI-Diagnostics (2024) with diagnostic sensitivity and specificity above 95%.
Where our devices go to work
The clinical setting where PAIN BOT, BIO BALANCE GUN, and PAIN Sign Board meet patients and clinicians — and prove what they were built for.
- PAIN BOTPain visualization + ultrasound / TENS therapy
- BIO BALANCE GUNAutomatic chiropractic activator
- SIGN BOARDLED spine chart for patient education
From diagnosis to global markets — handled in-house
Pain-data research, in-house manufacturing, clinical validation, and overseas regulatory approval — we cover the full pain-management chain ourselves.
Pain-data R&D
We collect and analyze bioelectrical-impedance and pain-severity data to research AI-based pain-management solutions.
In-house manufacturing
PAIN BOT and BIO BALANCE GUN are built at our Godeok factory in Yesan, with full inspection before shipment.
Clinical validation & papers
Validated through a Soonchunhyang University IRB-approved clinical study and published in MDPI-Diagnostics (SCI).
Global market entry
Medical-device approvals in five countries — Malaysia, Indonesia, Singapore, the Philippines, and Kyrgyzstan.
Considering adoption or partnership?
Product adoption, clinical materials, overseas distributorship — our team will respond quickly.
Send inquiry- Phone
- +82 41-338-6111
- sc.yu@redandblue.kr
- Address
- 73, Sangmongsandan 2-gil, Godeok-myeon, Yesan-gun, Chungcheongnam-do, Republic of Korea